Comparative Pharmacology
Head-to-head clinical analysis: NITRO DUR versus TRIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO DUR versus TRIDIL.
NITRO-DUR vs TRIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing cGMP, leading to vasodilation primarily in veins and arteries.
Nitroglycerin is a vasodilator that acts directly on vascular smooth muscle, causing relaxation. It primarily dilates venous capacitance vessels, reducing preload, and at higher doses dilates arterioles, reducing afterload. The mechanism involves nitric oxide-mediated activation of guanylyl cyclase, increasing cGMP levels.
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
Initial adult dose: 5 mcg/min IV via continuous infusion, titrated by 5 mcg/min every 3-5 minutes to achieve desired effect; usual therapeutic range 10-200 mcg/min.
None Documented
None Documented
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Terminal elimination half-life of nitroglycerin is 1-4 minutes; clinical effects are limited by rapid metabolism
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Renal (87% as inorganic nitrite/nitrate and metabolites), biliary/fecal (minimal, <1%)
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator